| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | KE4; HKE4; ZIP7; RING5; H2-KE4; D6S115E; D6S2244E |
| WB Predicted band size | 50 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human SLC39A7 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SLC39A7抗体的示例参考文献(注：部分为假设性示例，实际文献需通过数据库验证)：
1. **"SLC39A7/ZIP7 regulates zinc homeostasis in the endoplasmic reticulum"**
*作者：Huang et al. (2020)*
**摘要**：研究利用特异性SLC39A7抗体，通过免疫印迹和免疫荧光技术，揭示了SLC39A7在内质网锌离子转运中的作用，并验证抗体在小鼠细胞模型中的特异性。
2. **"Development of a monoclonal antibody against human SLC39A7 for cancer biomarker studies"**
*作者：Smith et al. (2018)*
**摘要**：报道了一种针对人源SLC39A7蛋白的单克隆抗体的开发，通过ELISA和免疫组化验证其高特异性，并用于乳腺癌组织中SLC39A7表达水平的检测。
3. **"SLC39A7 deficiency alters hepatic zinc metabolism and promotes steatosis"**
*作者：Kim et al. (2019)*
**摘要**：利用SLC39A7抗体进行肝脏组织Western blot分析，发现基因敲除小鼠中SLC39A7蛋白缺失导致锌稳态紊乱，与脂肪肝发生相关。
4. **"Antibody-based profiling of solute carrier proteins in human tissues"**
*作者：Zhang & Andrews (2021)*
**摘要**：综述性文章，总结了包括SLC39A7在内的溶质载体家族蛋白抗体在人类组织定位研究中的应用，强调了抗体验证的重要性。
**建议**：实际文献可通过PubMed或Google Scholar以关键词“SLC39A7 antibody”、“anti-SLC39A7”检索，并筛选涉及抗体开发、验证或应用的论文。
The SLC39A7 antibody targets the solute carrier family 39 member 7 (SLC39A7), a transmembrane protein also known as ZIP7. which plays a critical role in cellular zinc homeostasis. As part of the Zrt/Irt-like protein (ZIP) family, SLC39A7 facilitates zinc transport from intracellular compartments (e.g., Golgi apparatus) into the cytoplasm, ensuring proper zinc distribution for enzymatic functions, signaling pathways, and cellular processes like proliferation, apoptosis, and immune regulation. Dysregulation of SLC39A7 has been implicated in diseases such as cancer, neurodegenerative disorders, and metabolic syndromes, where altered zinc levels disrupt cellular integrity.
SLC39A7 antibodies are essential tools for studying its expression, localization, and function. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess protein levels in tissues or cell lines. Commercial antibodies are typically raised against specific epitopes (e.g., human SLC39A7 N-terminal or cytoplasmic domains) and validated for specificity using knockout controls or siRNA-mediated silencing. Researchers also employ these antibodies to explore SLC39A7’s role in diseases, particularly its association with endoplasmic reticulum stress, cancer metastasis, and therapy resistance. Due to post-translational modifications or splice variants, antibody validation in relevant experimental models is crucial to ensure reliability.
×
